vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.
New Fortress Energy Inc. is the larger business by last-quarter revenue ($326.2M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -259.7%, a 270.8% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -7.0%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-134.8M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -26.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
ANIP vs NFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $326.2M |
| Net Profit | $27.5M | $-847.1M |
| Gross Margin | — | 35.5% |
| Operating Margin | 14.1% | -193.0% |
| Net Margin | 11.1% | -259.7% |
| Revenue YoY | 29.6% | -7.0% |
| Net Profit YoY | 367.5% | -277.4% |
| EPS (diluted) | $1.14 | $-3.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $326.2M | ||
| Q3 25 | $227.8M | $240.3M | ||
| Q2 25 | $211.4M | $228.1M | ||
| Q1 25 | $197.1M | $384.9M | ||
| Q4 24 | $190.6M | $350.7M | ||
| Q3 24 | $148.3M | $446.0M | ||
| Q2 24 | $138.0M | $291.2M | ||
| Q1 24 | $137.4M | $609.5M |
| Q4 25 | $27.5M | $-847.1M | ||
| Q3 25 | $26.6M | $-263.0M | ||
| Q2 25 | $8.5M | $-546.5M | ||
| Q1 25 | $15.7M | $-175.4M | ||
| Q4 24 | $-10.3M | $-224.4M | ||
| Q3 24 | $-24.2M | $9.3M | ||
| Q2 24 | $-2.3M | $-88.9M | ||
| Q1 24 | $18.2M | $54.1M |
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 8.4% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 27.1% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 62.4% |
| Q4 25 | 14.1% | -193.0% | ||
| Q3 25 | 15.9% | -37.4% | ||
| Q2 25 | 6.6% | -170.3% | ||
| Q1 25 | 13.3% | -3.3% | ||
| Q4 24 | -2.3% | 65.0% | ||
| Q3 24 | -13.8% | 17.8% | ||
| Q2 24 | 3.7% | 12.3% | ||
| Q1 24 | 14.8% | 30.4% |
| Q4 25 | 11.1% | -259.7% | ||
| Q3 25 | 11.7% | -109.4% | ||
| Q2 25 | 4.0% | -239.6% | ||
| Q1 25 | 8.0% | -45.6% | ||
| Q4 24 | -5.4% | -64.0% | ||
| Q3 24 | -16.3% | 2.1% | ||
| Q2 24 | -1.7% | -30.5% | ||
| Q1 24 | 13.2% | 8.9% |
| Q4 25 | $1.14 | $-3.03 | ||
| Q3 25 | $1.13 | $-0.96 | ||
| Q2 25 | $0.36 | $-1.99 | ||
| Q1 25 | $0.69 | $-0.65 | ||
| Q4 24 | $-0.45 | $-1.10 | ||
| Q3 24 | $-1.27 | $0.03 | ||
| Q2 24 | $-0.14 | $-0.42 | ||
| Q1 24 | $0.82 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $226.5M |
| Total DebtLower is stronger | — | $8.2B |
| Stockholders' EquityBook value | $540.7M | $182.6M |
| Total Assets | $1.4B | $10.6B |
| Debt / EquityLower = less leverage | — | 44.78× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $226.5M | ||
| Q3 25 | $262.6M | $145.2M | ||
| Q2 25 | $217.8M | $551.1M | ||
| Q1 25 | $149.8M | $447.9M | ||
| Q4 24 | $144.9M | $492.9M | ||
| Q3 24 | $145.0M | $90.8M | ||
| Q2 24 | $240.1M | $133.0M | ||
| Q1 24 | $228.6M | $143.5M |
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $182.6M | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.3B | ||
| Q1 25 | $418.6M | $1.8B | ||
| Q4 24 | $403.7M | $1.9B | ||
| Q3 24 | $405.9M | $1.6B | ||
| Q2 24 | $455.8M | $1.6B | ||
| Q1 24 | $452.0M | $1.7B |
| Q4 25 | $1.4B | $10.6B | ||
| Q3 25 | $1.4B | $12.0B | ||
| Q2 25 | $1.3B | $12.0B | ||
| Q1 25 | $1.3B | $13.1B | ||
| Q4 24 | $1.3B | $12.9B | ||
| Q3 24 | $1.3B | $12.0B | ||
| Q2 24 | $920.8M | $11.4B | ||
| Q1 24 | $914.5M | $10.9B |
| Q4 25 | — | 44.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-76.2M |
| Free Cash FlowOCF − Capex | $29.1M | $-134.8M |
| FCF MarginFCF / Revenue | 11.8% | -41.3% |
| Capex IntensityCapex / Revenue | 0.5% | 18.0% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-76.2M | ||
| Q3 25 | $44.1M | $-171.0M | ||
| Q2 25 | $75.8M | $-329.0M | ||
| Q1 25 | $35.0M | $-7.2M | ||
| Q4 24 | $15.9M | $445.3M | ||
| Q3 24 | $12.5M | $-20.0M | ||
| Q2 24 | $17.4M | $113.9M | ||
| Q1 24 | $18.3M | $63.0M |
| Q4 25 | $29.1M | $-134.8M | ||
| Q3 25 | $38.0M | $-231.6M | ||
| Q2 25 | $71.8M | $-726.7M | ||
| Q1 25 | $32.5M | $-262.3M | ||
| Q4 24 | $13.5M | $-210.3M | ||
| Q3 24 | $7.7M | $-367.0M | ||
| Q2 24 | $13.0M | $-493.2M | ||
| Q1 24 | $13.7M | $-457.9M |
| Q4 25 | 11.8% | -41.3% | ||
| Q3 25 | 16.7% | -96.4% | ||
| Q2 25 | 34.0% | -318.6% | ||
| Q1 25 | 16.5% | -68.2% | ||
| Q4 24 | 7.1% | -60.0% | ||
| Q3 24 | 5.2% | -82.3% | ||
| Q2 24 | 9.4% | -169.3% | ||
| Q1 24 | 10.0% | -75.1% |
| Q4 25 | 0.5% | 18.0% | ||
| Q3 25 | 2.7% | 25.2% | ||
| Q2 25 | 1.9% | 174.4% | ||
| Q1 25 | 1.3% | 66.3% | ||
| Q4 24 | 1.3% | 187.0% | ||
| Q3 24 | 3.2% | 77.8% | ||
| Q2 24 | 3.2% | 208.4% | ||
| Q1 24 | 3.3% | 85.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -2.15× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
NFE
Segment breakdown not available.
